Promising cocktail may turn inoperable stomach cancer into surgical candidates

NCT ID NCT05177068

Ongoing Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of three drugs—fruquintinib, sintilimab, and SOX (S-1 plus oxaliplatin)—as a pre-surgery treatment for people with stage IV gastric cancer that cannot be fully removed. The goal is to shrink the tumor enough to allow complete surgical removal. The study includes 42 participants and measures how many achieve successful surgery and how the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fruquintinib, sintilimab, S-1, and oxaliplatin
What this could lead to: If successful, this combination could help more patients with advanced gastric cancer become eligible for surgery, potentially improving survival and cure rates.
What could go wrong: This is a small, early-phase trial with only 42 participants, so results may not apply broadly. The drug combo can cause serious side effects like immune reactions, bleeding, or liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

Henan Tumor Hospital

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.